β-N-methylamino-L-alanine (BMAA) suppresses cell cycle progression of non-neuronal cells

Saki Okamoto1,3, Shigeyuki Esumi2, Kayoko Hamaguchi-Hamada1 & Shun Hamada1

β-N-methylamino-L-alanine (BMAA), a natural non-proteinaceous amino acid, is a neurotoxin produced by a wide range of cyanobacteria living in various environments. BMAA is a candidate environmental risk factor for neurodegenerative diseases such as amyotrophic lateral sclerosis and Parkinson-dementia complex. Although BMAA is known to exhibit weak neuronal excitotoxicity via glutamate receptors, the underlying mechanism of toxicity has yet to be fully elucidated. To examine the glutamate receptor-independent toxicity of BMAA, we investigated the effects of BMAA in non-neuronal cell lines. BMAA potently suppressed the cell cycle progression of NIH3T3 cells at the G1/S checkpoint without inducing plasma membrane damage, apoptosis, or overproduction of reactive oxygen species, which were previously reported for neurons and neuroblastoma cells treated with BMAA. We found no evidence that activation of glutamate receptors was involved in the suppression of the G1/S transition by BMAA. Our results indicate that BMAA affects cellular functions, such as the division of non-neuronal cells, through glutamate receptor-independent mechanisms.
demonstrated that BMAA was misincorporated into proteins in place of L-serine in non-neuronal and neuroblastoma cells. In non-neuronal cells, BMAA induced intracellular autofluorescent bodies, which are indicative of protein aggregation. These findings suggest that both non-neuronal cells and neurons are affected by BMAA through glutamate receptor-independent mechanisms.

To gain insight into BMAA toxicity, the effects of BMAA on the cellular function of non-neuronal cells and neurons need to be determined in an unbiased manner. To date, only a few studies have focused on BMAA toxicity in non-neuronal cells, specifically olfactory ensheathing (OE) cells, which are glial cells that wrap around the olfactory nerves. BMAA induced cell membrane damage in OE cells by markedly increasing the production of reactive oxygen species (ROS), and significantly enhancing mitochondrial activity and Ca\(^{2+}\) influx. However, because glial cells express glutamate receptors, it is unclear whether these adverse effects of BMAA on OE cells occur independently of the activation of glutamate receptors.

To examine whether BMAA affects cellular function in an unbiased manner, we investigated the effects of BMAA on a mouse fibroblast cell line, NIH3T3. We demonstrated that BMAA potently suppresses the cell cycle progression of NIH3T3 cells via glutamate receptor-independent mechanisms without inducing cell membrane damage, apoptosis, or overproduction of ROS.

**Results**

To investigate the effects of BMAA on non-neuronal cells, we initially analyzed the effects of BMAA on NIH3T3 cells, a fibroblast cell line. Incubation in medium containing 1 or 3 mM BMAA significantly suppressed increases in NIH3T3 cell number to a greater extent than in control cultures treated with vehicle (Fig. 1a). In contrast, glutamate, alanine, and serine did not suppress the increase in NIH3T3 cell number. To clarify whether increases in other non-neuronal cells were sensitive to BMAA, we conducted these experiments in HEK293T cells. We found that BMAA also suppressed increases in HEK293T cell number; however, the degree of suppression was less than that observed for NIH3T3 cells (Fig. 1b).

One possible cause of the suppressed proliferation of BMAA-treated cells is cell death induced by BMAA toxicity. To examine this possibility, we used a lactate dehydrogenase (LDH) assay to quantify LDH leakage into the culture supernatant from dying or dead cells. LDH leakage in the culture supernatants of NIH3T3 cells after BMAA treatment was similar to that from control cells treated with vehicle, glutamate, or alanine (Table 1). Therefore, BMAA did not induce cell death by compromising NIH3T3 cell membranes.
BMAA induces apoptosis of neurons and neuroblastoma cells\textsuperscript{1,21,22,27}. To detect apoptosis of BMAA-treated cells, we examined the activation of the caspase cascade using anti-active caspase-3 immunostaining. We found little to no active caspase-3-positive profiles with chromatin condensation among BMAA-treated cells or control cells (Table 2).

The absence of apparent cell death of BMAA-treated cells prompted us to investigate whether BMAA suppresses cell cycle progression. To examine cell cycle progression in NIH3T3 cells treated with BMAA, we labeled cells with 5-bromo-2\textsuperscript{′}-deoxyuridine (BrdU) for 2 h in medium containing BMAA. The ratio of BrdU-positive nuclei to DAPI-stained nuclei (the BrdU labeling index) was significantly lower for BMAA-treated cells than vehicle-treated control cells (Fig. 2a), suggesting that BMAA suppressed cell cycle progression. To identify which checkpoints were affected by BMAA, the cell cycle was synchronized at the G1 phase by serum starvation and cells were then cultured in normal medium with BMAA. BMAA markedly suppressed the G1/S transition (Fig. 2b); the BrdU labeling index for cells treated with 1 and 3 mM BMAA was 10.1% and 5.7%, respectively, whereas that for control cells was 56.2%. Furthermore, the BrdU labeling index for alanine-treated cells was similar to that for control cells (Fig. 2c,d).

We also analyzed the cell cycle progression of BMAA-treated cells using flow cytometry (Fig. 3). After synchronized NIH3T3 cells were cultured with BMAA or vehicle, the DNA content of cells was examined when the majority of control cells entered the G2/M phase. In contrast to control cells, which mostly had signals corresponding to the G2/M phase, the majority of BMAA-treated cells had DNA signals corresponding to the G1/G0 phase (Fig. 3b).

We then examined whether the BMAA-mediated suppression of the G1/S transition required activation of glutamate receptors, given that NIH3T3 cells may express glutamate receptors\textsuperscript{28}, and that the concentrations of BMAA (1 and 3 mM) used in the present study were previously shown to induce excitotoxicity in neurons through NMDA glutamate receptor activation\textsuperscript{7,19}. The excitotoxicity of BMAA is known to be strongly dependent on bicarbonate as a cofactor\textsuperscript{7,19}. We therefore examined suppression of the G1/S transition using BMAA in Leibovitz’s L-15 medium, which does not contain bicarbonate\textsuperscript{29}. The BrdU labeling index of BMAA-treated cells in L-15 medium was significantly lower than that of vehicle-treated control cells (Fig. 4a); however, the effects of BMAA on the G1/S transition appeared to be weaker in L-15 medium than in DMEM. We then examined whether the bicarbonate in L-15 medium enhanced suppression of the G1/S transition by BMAA. While the addition of 10 mM bicarbonate was previously shown to be sufficient for BMAA to induce excitotoxicity in neurons\textsuperscript{7}, it did not enhance the BMAA-mediated suppression of the G1/S transition in L-15 medium. Instead, the bicarbonate alleviated the BMAA-mediated suppression of this transition (Fig. 4a).

To confirm this hypothesis, we examined the G1/S transition in NIH3T3 cells treated with

| Treatment | % LDH activity ± SEM |
|-----------|----------------------|
| Triton X-100 | 100.00 ± 1.570 |
| Control | 2.44 ± 0.060 |
| BMAA | 2.26 ± 0.040 |
| 3 mM | 2.86 ± 0.169 |
| Glutamate | 2.16 ± 0.087 |
| 3 mM | 2.90 ± 0.247 |
| Alanine | 2.04 ± 0.075 |
| 3 mM | 1.44 ± 0.075*** |
| Serine | 1.98 ± 0.037 |
| 3 mM | 1.94 ± 0.103 |

Table 1. BMAA had negligible effects on the cellular integrity of NIH3T3 cells. We examined LDH leakage from cells treated with BMAA, glutamate, alanine, or serine for 48 h. Results are expressed as a ratio of the control, in which all cells were lysed with 1.5% Triton X-100. ***P < 0.001 significantly different from the vehicle control (n = 5).

| Treatment duration | Reagent | Nuclear profile | Active caspase-3-positive cells | % |
|--------------------|---------|-----------------|-------------------------------|----|
| 48 h               | Control | 2939            | 8                             | 0.14 |
| 48 h               | BMAA    | 2930            | 2                             | 0.07 |
| 48 h               | Alanine | 2345            | 0                             | 0   |
| 24 h               | Etoposide | 1490          | 191                           | 12.8 |

Table 2. BMAA did not activate the caspase cascade in NIH3T3 cells. After cells were cultured in medium containing 1 mM BMAA or alanine for 48 h, we examined active caspase-3 immunoreactive cells with chromatin condensation (active caspase-3-positive cells). Control cells were treated with vehicle. We used 50 μM etoposide, an inducer of apoptosis, as a positive control. Nuclear profiles were the total number of nuclei examined by DAPI staining in each experiment.
1 mM glutamate, a concentration that is sufficient to induce nearly complete cell death in several neuroblastoma cell lines. The BrdU labeling index of glutamate-treated cells (68.4%) was similar to that in control cells (61.2%) (Fig. 4b). Furthermore, we examined the effects of MK-801, a non-competitive NMDA glutamate receptor antagonist, on the suppression of the G1/S transition by BMAA because MK-801 treatment rescued neuronal cell death induced by BMAA in previous studies. However, MK-801 did not counter the suppressive effects of BMAA on the G1/S transition in NIH3T3 cells (Fig. 4b).

Our results from the BrdU labeling and flow cytometry experiments indicate that BMAA potently arrested cell cycle progression at the G1/S checkpoint without activating glutamate receptors. Although G1 arrest may be induced by various factors, we focused on the overproduction of ROS, which has been repeatedly observed in BMAA-treated cells. To examine ROS production, we performed a dichlorofluorescein oxidation assay; however, we did not observe any significant differences in the generation of ROS between BMAA-treated NIH3T3 cells and control cells (Fig. 5).

A previous study demonstrated that co-incubation with serine and BMAA reduced the incorporation of BMAA into cellular proteins as well as its neurotoxicity. We therefore investigated whether co-incubation with serine would alleviate the suppressed proliferation of BMAA-treated NIH3T3 cells. No significant differences were observed in the number of cells after incubation in medium containing BMAA with or without 3 mM serine for 96 h (Fig. 6).

**Discussion**

BMAA is an excitatory neurotoxin, and few studies have focused on its effects on non-neuronal cells. We revealed that BMAA potently suppressed the cell cycle progression of NIH3T3 cells, a fibroblast cell line, at the G1/S checkpoint. Apart from G1 arrest, we found no evidence of any detrimental effects on NIH3T3 cells following BMAA exposure, including cell membrane damage, apoptosis, or ROS overproduction, which have previously
been reported in neuronal and OE cells\(^1,3,7,19,21,22,25\). Although we clearly demonstrated that BMAA induced G1 arrest in NIH3T3 cells, we cannot dismiss the possibility that it may induce cell cycle arrest at other checkpoints. A previous study demonstrated that BMAA was cytotoxic to OE cells\(^25\) and arrested cell cycle progression at the G2/M checkpoint\(^24\). BMAA may therefore also arrest the cell cycle of NIH3T3 cells at the G2/M checkpoint.

We found no evidence that glutamate receptor activation was involved in the G1 arrest of BMAA-treated NIH3T3 cells. Further, although bicarbonate has been shown to be essential for the excitotoxic effect of BMAA in neurons\(^7,19\), it was not required for BMAA-mediated suppression of the G1/S transition. Incubation with 1 mM glutamate, a concentration that is sufficient to induce cell death in several neuroblastoma cell lines, did not suppress the proliferation or G1/S transition of NIH3T3 cells. Furthermore, MK-801, which has been shown to attenuate neuronal cell death induced by BMAA, did not block the BMAA-mediated suppression of the G1/S transition\(^1,3,18\). These results indicate that BMAA induces G1 arrest of non-neuronal cells through glutamate receptor-independent mechanisms.

Arrest in the G1 phase of the cell cycle may occur due to various factors including the overproduction of ROS\(^30\), ER stress\(^31,32\), deficiency in nutrients and growth factors, and DNA damage. However, our results indicate that the overproduction of ROS is an unlikely cause of G1 arrest in BMAA-treated cells. Previous studies have shown that BMAA is misincorporated into cellular proteins\(^21–23\), and autofluorescence indicating protein aggregation has been reported in BMAA-treated fibroblasts\(^22\). Intracellular protein aggregation may induce ER stress. BMAA reportedly causes ER stress in neuroblastoma cells via glutamate receptor-independent mechanisms\(^21\). Therefore, future studies should examine elevations in ER stress markers in BMAA-treated NIH3T3 cells.

Another possible cause of G1 arrest is DNA damage. BMAA induces DNA breaks in primary neurons, and excess ROS production has been suggested to cause BMAA-induced DNA damage\(^1\). However, we did not observe overproduction of ROS in BMAA-treated cells, suggesting that BMAA does not cause excessive DNA damage in NIH3T3 cells.

Nutrient deficiency is another possible cause of G1 arrest. BMAA is transported by L-type amino acid transporter 1 and possibly by other transporters\(^31\). BMAA may therefore be a competitive inhibitor of amino acid transporters and enzymes required for amino acid metabolism. The effects of BMAA on G1/S transition appeared to be weaker in L-15 medium than in normal medium (DMEM). L-15 medium is an amino acid-rich medium that contains alanine and asparagine (neither of which are present in DMEM), and five- to eight-fold higher concentrations of several amino acids, including arginine, glycine, histidine, and serine, than DMEM. These amino acids may compete with BMAA for transport or metabolism.

The addition of bicarbonate to L-15 medium unexpectedly alleviated the BMAA-mediated suppression of G1/S transition in NIH3T3 cells (Fig. 3a). Addition of bicarbonate to L-15 medium was previously shown to markedly enhance DNA synthesis and the proliferation of primary cultured hepatocyte cells\(^33,34\), an effect which is thought to be influenced by the high levels of amino acids in L-15 medium\(^34\). It is possible that the addition of bicarbonate to L-15 medium activates amino acid metabolism for DNA synthesis in NIH3T3 cells, and that this activated amino acid metabolism may mitigate the suppressive effect of BMAA on cell cycle progression.
Figure 4. BMAA suppressed the G1/S transition of NIH3T3 cells without activating glutamate receptors. (a) After G1-synchronized cells were cultured in bicarbonate-free L-15 medium with 10% FBS containing BMAA or vehicle (open bar), 0.5% FBS (Low Serum, a positive control for cell cycle arrest) for 16 h, they were labeled with BrdU for 2 h. To examine whether the addition of bicarbonate to L-15 medium enhances the BMAA-mediated suppression of the G1/S transition, G1-synchronized cells were cultured in L-15 medium with 10% FBS containing BMAA and bicarbonate (10 mM NaHCO₃ + BMAA) or BMAA and NaCl (10 mM NaCl + BMAA) as a negative control. Error bars represent SEM, n = 3. *P < 0.05. ***P < 0.001 significantly different from the vehicle control value. (b) After G1-synchronized cells were cultured in DMEM containing BMAA, BMAA with 50 μM MK-801, alanine with 50 μM MK-801, glutamate or vehicle (open bar) for 16 h, they were labeled with BrdU for 2 h. Error bars represent SEM, n = 3. ***P < 0.001.

Figure 5. BMAA did not enhance ROS production in NIH3T3 cells. ROS production in cells treated with BMAA, glutamate, alanine, serine, or hydrogen peroxide (H₂O₂, positive control) was measured using a DCFDA assay. Data were normalized to the vehicle control values (open bar). Error bars represent SEM, n = 5.
Amino acid starvation or impaired amino acid metabolism may inhibit the nutrient-sensitive mammalian target of rapamycin (mTOR) pathway or activate the general control nonderepressible 2 (GCN2) pathway to protect cells against amino acid starvation. Inhibition of the mTOR pathway suppresses cell cycle progression at the G1 phase, and activation of the GCN2 pathway also leads to G1 arrest. Further studies are needed to examine whether these pathways are involved in G1 arrest induced by BMAA.

A previous study showed that BMAA was misincorporated into proteins in place of serine, and that co-incubation with serine reduced the toxicity of BMAA in neuroblastoma cells. These findings prompted us to examine whether co-incubation with serine also attenuates the BMAA-mediated suppression of NIH3T3 cell proliferation; however, such attenuation was not observed. The finding that incubation in amino acid-rich L-15 medium appeared to mitigate the suppression of the G1/S transition in BMAA-treated cells, as described above, suggests that amino acids other than serine may compete with BMAA for transport or metabolism in NIH3T3 cells. Alternatively, the ratio of the concentration of serine to BMAA (1:1 and 3:1) used in the present study may have been insufficient for alleviation of the suppressed proliferation of BMAA-treated cells given that the concentration of serine used in the previous study was ten-fold higher than that of BMAA.

The mechanisms by which BMAA-induced G1 arrest contributes to the pathogenesis of ALS/PDC is currently unknown because most neurons in the adult brain are post-mitotic. However, neurons may reinitiate cell cycle progression under pathological conditions such as ischemia-hypoxia, excitotoxicity, or neurodegenerative diseases. Although neuronal cell cycle re-entry may precede apoptosis, neurons in neurodegenerative diseases may actively re-enter the cell cycle and survive for long periods as tetraploid neurons. The BMAA-induced suppression of cell cycle progression may therefore inhibit the production of tetraploid neurons and accelerate neuronal loss in neurodegenerative diseases, including ALS/PDC.

A recent study reported that an injection of a sub-toxic dose of BMAA into the cerebrospinal fluid delayed the progression of ALS in an ALS mouse model, which was suggested to have occurred due to prevention of the down-regulation of Na+/Ca2+ exchanger 3 (NCX3). NCX3 has been reported to be involved in cell cycle progression. The subcellular localization of NCX3 changes during the cell cycle: NCX3 is detected in the plasma membrane during the S or M phases, but is mainly observed in the ER membrane in the G0/G1 phase. Moreover, forced expression of genetically modified NCX3 transported into the ER membrane perturbed cell cycle progression at the G1/S checkpoint. Therefore, future studies should clarify whether BMAA affects the expression of NCX3 in NIH3T3 cells.

In conclusion, we found that BMAA suppressed cell cycle progression in the mouse fibroblast cell line, NIH3T3, at least at the G1/S checkpoint, without activating glutamate receptors. As non-neuronal cell lines can easily be analyzed for metabolic changes and functional alterations, the present results provide a new perspective to understand the mechanisms by which BMAA affects cellular function.

**Materials and Methods**

All amino acids used in the present study were the L-form. BMAA (Sigma-Aldrich) was dissolved in 0.1 M phosphate buffer (pH 7.3) to 50 mM before being added to culture media. Since the excitotoxicity of BMAA is dependent on bicarbonate, we used BMAA solution that was neutralized for sodium bicarbonate (50 mM BMAA, 50 mM phosphate buffer, and 100 mM sodium bicarbonate, pH 7.3) in some experiments.

NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (Gibco) in 5% CO2 at 37°C.

**Treatment of culture cells with BMAA.** NIH3T3 and HEK293T cells were seeded on 12- and 24-well culture plates, respectively, at a density of 1.2 × 104 cells/well. This seeding density for NIH3T3 cells avoids contact inhibition. After cells were precultured for 16 h in DMEM containing 10% FBS (DMEM-FBS), medium was changed to DMEM-FBS containing BMAA (1 or 3 mM) for 48 h. To examine the effects of co-incubation with serine on the BMAA-induced suppression of NIH3T3 cell proliferation, cells were cultured in DMEM-FBS containing BMAA with 3 mM serine for 96 h after the preculture. Cells were then dissociated with 0.25% trypsin.
in phosphate-buffered saline (PBS) containing 0.02% ethylenediaminetetraacetic acid (EDTA). The number of cells was counted under a phase microscope using a hemocytometer. In a given experiment, all cell counts were performed by the same operator.

**LDH assay.** To evaluate the cellular toxicity of BMAA, we examined the amount of LDH in culture medium released from membrane-damaged cells using a Cytotoxicity LDH Assay Kit-WST (DOJINDO Laboratories, Kumamoto, Japan). NIH3T3 cells were seeded on a 96-well culture plate according to the manufacturer’s protocol. After preculture for 16 h, medium was changed to DMEM-FBS containing BMAA, amino acids, or vehicle, and cells were cultured for 48 h prior to the LDH assay. Culture supernatants (100 µL) were transferred to another 96-well plate, and the substrate solution for the LDH assay was added to each well. After incubating for 30 min, LDH activity was assessed by measuring the absorbance at 490 nm. The amount of LDH released was expressed as a ratio of the control, in which all cells were lysed with 1.5% Triton X-100. The results obtained were normalized to the total protein content in each well to correct for well-to-well variations. Protein content was measured using a BCA protein assay kit (Thermo Fisher Scientific) after residual cells were solubilized with 1% sodium lauryl sulfate.

**ROS measurement.** Oxidative stress was assayed by measuring dichlorofluorescein oxidation according to a previously reported method with modifications. In this experiment, we used DMEM without phenol red to avoid interference with fluorescence measurements. After cells were cultured in DMEM-FBS for 16 h, they were incubated in medium containing BMAA or amino acids for 3 h in the presence of 10 µM 5(6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H$_2$DCFDA, Setareh Biotech, USA). Cells were then rinsed three times with DMEM, and fluorescence from the oxidation product of carboxy-H$_2$DCFDA was measured using a fluorescent plate reader (EnSpire, PerkinElmer) with a 485-nm excitation filter and 538-nm emission filter. Background fluorescence (no carboxy-H$_2$DCFDA added) was subtracted and data were presented as a % of the mean value calculated from control cultures (carboxy-H$_2$DCFDA added, no treatment with BMAA).

**Analysis of BrdU incorporation.** Approximately 1.2 × 10^4 cells were seeded onto a coverslip in each well of a 12-well culture plate and preincubated for 16 h in DMEM-FBS. Medium was then changed to DMEM-FBS containing BMAA (1 or 3 mM) or alanine for the control. After 46 h, cells were pulse-labeled with 10 µM BrdU for 2 h. All experiments were performed in triplicate.

To examine G1/S progression, we synchronized cells at the G1 phase by incubating in DMEM containing 0.5% FBS for 48 h. Cells were then dissociated and seeded onto coverslips in a 12-well plate at 2 × 10^4 cells/well. After the incubation in DMEM containing 10% FBS with BMAA, glutamate, alanine, or vehicle for 16 h, cells were pulse-labeled with 10 µM BrdU for 2 h. To examine the effects of bicarbonate on the suppression of the G1/S transition by BMAA, we used Leibovitz’s L-15 medium instead of DMEM in air at 37°C. Cells in L-15 medium containing 10 mM sodium bicarbonate were incubated in 2.1% CO$_2$ to maintain the pH of the medium. Furthermore, the effects of NMDA receptor blockade on the suppression of the G1/S transition by BMAA were investigated using (+)-MK-801 maleate in combination with BMAA.

After incorporation of BrdU, cells were fixed in a mixture of methanol and acetic acid (3:1) for 30 min. After rinses with PBS, cells were incubated with blocking reagent (Blocking One; Nacalai Tesque, Japan) containing 5% normal goat serum (Invitrogen) for 1 h. Cells were then incubated with a mouse anti-BrdU antibody (dilution 1:1000, clone BU-33, Sigma-Aldrich) diluted with PBST containing 5% blocking reagent at 4°C overnight. After rinses with PBST and PBS, cells were incubated with Alexa 488-labeled goat anti-mouse IgG (Thermo Fischer Scientific) diluted 1:500 in PBST containing 5% blocking reagent at room temperature for 1 h. After rinses with PBST and PBS, cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, 1 µg/mL) diluted in PBS for 3 min. After several rinses with PBS, coverslips were mounted onto slide glasses with mounting medium. Cells were examined under a fluorescent microscope (Eclipse E800, Nikon) using a 20x objective, and images (at least five fields per culture) were randomly captured using a digital camera system (DXM1200F, Nikon). We then counted the number of DAPI-stained cells and BrdU-labeled cells on a liquid crystal monitor equipped with a digital camera. The BrdU-labeling index was calculated as the ratio of BrdU-positive nuclei to DAPI-stained nuclei. In each culture, we examined at least 50 DAPI-stained nuclei.

**Active caspase-3 immunostaining.** Approximately 1.2 × 10^4 cells were seeded onto a coverslip in each well of 12-well culture plates and preincubated for 16 h in DMEM-FBS. Medium was then changed to DMEM-FBS containing 1 mM BMAA, 1 mM alanine, or 50 µM etoposide, an inducer of apoptosis in NIH3T3 cells, and the cells were cultured for 48 h.

Cells were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 30 min. After rinses with PBST and PBS, cells were incubated with blocking reagent containing 5% normal goat serum for 1 h. Cells were then incubated with a rabbit anti-active caspase-3 antibody (dilution 1:500, clone C92-605, BD Biosciences) diluted with PBST containing 5% blocking reagent at 4°C overnight. After rinses with PBST and PBS, cells were incubated with Alexa 488-labeled goat anti-rabbit IgG (Thermo Fisher Scientific) diluted 1:1000 in PBST containing 5% blocking reagent at room temperature for 1 h. After rinses with PBST and PBS, cells were counterstained with DAPI for 3 min. After several rinses with PBS, coverslips were mounted onto slide glasses with mounting medium. Cells were examined using a fluorescent microscope and images were captured by a digital camera. At least 500 DAPI-stained cells were examined per sample.
Flow cytometry. NIH3T3 cells were synchronized at the G1 phase by incubating in low serum medium. Synchronized cells were dissociated and seeded at 2.8 × 10⁴ cells/10-cm dish. After incubating in DMEM-FBS containing 1 mM BMAA or vehicle for 22 h, cells were harvested via trypsinization and centrifuged at 200 × g for 5 min. Cells were resuspended and incubated in propidium iodide (PI)-staining solution containing 50 μg/mL PI, 0.25 mg/mL RNase A, 0.2% NP-40, 250 mM sucrose, and 5% DMSO in 4 mM sodium citrate buffer (pH 7.6) at 4°C for 30 min following an incubation at 37°C for 15 min to digest RNA. The fluorescence signal from 10,000 cells was analyzed using a flow cytometer (BD FACSDose, BD Biosciences).

Statistical analysis. All data, except those from the BrdU incorporation experiment, were examined using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer HSD test. Data from the BrdU incorporation experiment were examined using repeated ANOVA followed by the Tukey-Kramer HSD test. All analyses were performed using JMP Pro 12 (SAS Institute).

Data Availability Statement
All data generated or analyzed during this study are included in this published article.

References
1. Chiu, A. S. et al. Excitotoxic potential of the cyanotoxin beta-methyl-amino-L-alanine (BMAA) in primary human neurons. *Toxicol Sci* **60**, 1159–1165, https://doi.org/10.1093/toxsci/kfj075 (2012).
2. Karlsson, O., Roman, E., Berg, A. L. & Brittebo, E. B. Early hippocampal cell death, and late learning and memory deficits in rats exposed to the environmental toxin BMAA (beta-N-methylamino-L-alanine) during the neonatal period. *Behav Brain Res* **219**, 310–320, https://doi.org/10.1016/j.bbr.2011.01.056 (2011).
3. Lobner, D., Piana, P. M., Salous, A. K. & Peoples, R. W. Beta-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. *Neurobiol Dis* **35**, 360–366, https://doi.org/10.1016/j.nbd.2006.07.002 (2007).
4. Rao, S. D., Banack, S. A., Cox, P. A. & Weiss, J. H. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. *Exp Neurol* **201**, 244–252, https://doi.org/10.1016/j.expneurol.2006.04.017 (2006).
5. Ross, S. M., Seelig, M. & Spencer, S. P. Specific antagonism of excitotoxic action of ‘uncommon’ amino acids assayed in organotypic mouse cortical cultures. *Brain Res* **425**, 120–127 (1987).
6. Spencer, P. S. et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a constant excitotoxic toxin. *Science* **237**, 517–522 (1987).
7. Weiss, J. H. & Choi, D. W. Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. *Science* **241**, 973–975 (1988).
8. Yin, H. Z. et al. Intrathral infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. *Exp Neurol* **261**, 1–9, https://doi.org/10.1016/j.expneurol.2014.06.003 (2014).
9. Cox, P. A. et al. Diverse taxa of cyanobacteria produce beta-N-methylamino-L-alanine, a neurotoxic amino acid. *Proc Natl Acad Sci USA* **102**, 5074–5078, https://doi.org/10.1073/pnas.0501526102 (2005).
10. Cox, P. A., Banack, S. A. & Murch, S. J. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. *Proc Natl Acad Sci USA* **100**, 13380–13383, https://doi.org/10.1073/pnas.0923580810 (2003).
11. Jonasson, S. et al. Transfer of a cyanobacterial neurotoxin within a temperate aquatic ecosystem suggests pathways for human exposure. *Proc Natl Acad Sci USA* **107**, 9252–9257, https://doi.org/10.1073/pnas.0914417107 (2010).
12. Masseret, E. et al. Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France. *PLoS One* **8**, e83406, https://doi.org/10.1371/journal.pone.0083406 (2013).
13. Banack, S. A. et al. Detection of cyanobacteria, beta-N-methylamino-L-alanine and microcystins, from a lake surrounded by cases of amyotrophic lateral sclerosis. *Toxins (Basel)* **7**, 322–336, https://doi.org/10.3390/toxins7020322 (2015).
14. Kurland, L. T. Amyotrophic lateral sclerosis and Parkinson’s disease complex on Guam linked to an environmental neurotoxin. *Trends Neurosci* **11**, 51–54 (1988).
15. Cox, P. A. & Sacks, O. W. Cyclad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. *Neurology* **58**, 956–959 (2002).
16. Caller, T. A. et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms. *Amytrophic Lateral Scler* **10** (Suppl 2), 101–108, https://doi.org/10.3109/17482969903728485 (2009).
17. Spencer, P. S. et al. Lathyribism: evidence for role of the neuroexcitatory aminoacid BOAA. *Lancet* **2**, 1066–1067 (1986).
18. Liu, X., Rast, T., Zapata, J. & Lobner, D. Beta-N-methylamino-L-alanine induces oxidative stress and glutamate release through action on system Xc(-). *Exp Neurol* **217**, 429–433, https://doi.org/10.1016/j.expneurol.2009.04.002 (2009).
19. Weiss, J. H., Christine, C. W. & Choi, D. W. Bicarbonate dependence of glutamate receptor activation by beta-N-methylamino-L-alanine: channel recording and study with related compounds. *Neuron* **3**, 321–326 (1989).
20. Lee, M. & McGeer, P. L. Weak BMAA toxicity compares with that of the dietary supplement beta-alanine. *Neurobiol Aging* **33**, 1440–1447, https://doi.org/10.1016/j.neurobiolaging.2010.11.024 (2012).
21. Okle, O., Stemmer, K., Deschl, U. & Dietrich, D. R. L-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations. *Toxicol Sci* **131**, 217–224, https://doi.org/10.1093/toxsci/kfs291 (2013).
22. Dunlop, R. A., Cox, P. A., Banack, S. A. & Rodgers, K. J. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. *PLoS One* **8**, e75376, https://doi.org/10.1371/journal.pone.0075376 (2013).
23. Karlsson, O., Jiang, L., Andersson, M., Ilag, L. L. & Brittebo, E. B. Protein association of the neurotoxin and non-protein amino acid BMAA (beta-N-methylamino-L-alanine) in the liver and brain following neonatal administration in rats. *Toxicol Lett* **226**, 1–5, https://doi.org/10.1016/j.toxlet.2014.01.027 (2014).
24. Chiu, A. S. et al. Global cellular responses to beta-methyl-amino-L-alanine (BMAA) by olfactory ensheathing glial cells (OEC). *Toxicinon* **99**, 136–145, https://doi.org/10.1016/j.toxinon.2015.03.009 (2015).
25. Chiu, A. S. et al. Gliotoxicity of the cyanotoxin, beta-methyl-L-alanine (BMAA). *Sci Rep* **3**, 1482, https://doi.org/10.1038/srep01482 (2013).
26. Gallo, V. & Ghiani, C. A. Glutamate receptors in glia: new cells, new inputs and new functions. *Trends Pharmacol Sci* **21**, 252–258 (2000).
27. Munoz-Saez, E. et al. Analysis of beta-N-methylamino-L-alanine (L-BMAA) neurotoxicity in rat cerebellum. *Neurology* **48**, 192–205, https://doi.org/10.1212/wnl.2004.04.001 (2015).
28. Okutsu, S., Hatakeyama, H., Kanazki, M., Tsukahara, H. & Nagatomi, R. Electric pulse stimulation induces NMDA glutamate receptor mRNA in NIH-3T3 mouse fibroblasts. *Tohoku J Exp Med* **215**, 181–187 (2008).
29. Leibovitz, A. The Growth and Maintenance of Tissue-Cell Cultures in Free Gas Exchange with the Atmosphere. *Am J Hyg* **78**, 173–180 (1963).

www.nature.com/scientificreports/
30. Boonstra, J. & Post, J. A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. *Gene* **337**, 1–13, https://doi.org/10.1016/j.gene.2004.04.032 (2004).
31. Brewer, J. W., Hendershot, L. M., Sherr, C. J. & Diehl, J. A. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. *Proc Natl Acad Sci U S A* **96**, 8505–8510 (1999).
32. Szegedi, E., Fitzgerald, U. & Samali, A. Caspase-12 and ER-stress-mediated apoptosis: the story so far. *Ann NY Acad Sci* **1010**, 186–194 (2003).
33. Mitaka, T., Sattler, G. L. & Pitot, H. C. The bicarbonate ion is essential for efficient DNA synthesis by primary cultured rat hepatocytes. *In Vitro Cell Dev Biol* **27A**, 549–556 (1991).
34. Mitaka, T., Sattler, G. L. & Pitot, H. C. Amino acid-rich medium (Leibovitz L-15) enhances and prolongs proliferation of primary cultured rat hepatocytes in the absence of serum. *J Cell Physiol* **147**, 495–504, https://doi.org/10.1002/jcp.1041470316 (1991).
35. Gonzalez, A. & Hall, M. N. Nutrient sensing and TOR signaling in yeast and mammals. *EMBO J* **36**, 397–408, https://doi.org/10.15252/embj.201696010 (2017).
36. Abraham, R. T. & Wiederrecht, G. J. Immunopharmacology of rapamycin. *Ann Rev Immunol* **14**, 483–510, https://doi.org/10.1146/annurev.immunol.14.1.483 (1996).
37. Fingar, D. C. *et al.* mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. *Mol Cell Biol* **24**, 200–216 (2004).
38. Krohn, M., Skjolberg, H. C., Soltani, H., Grallert, B. & Boye, E. The G1-S checkpoint in fission yeast is not a general DNA damage checkpoint. *J Cell Sci* **121**, 4047–4054, https://doi.org/10.1242/jcs.035428 (2008).
38. Tvegard, T. *et al.* A novel checkpoint mechanism regulating the G1/S transition. *Genes Dev* **21**, 649–654, https://doi.org/10.1101/gad.421807 (2007).
39. Copani, A. *et al.* Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? *Trends Neurosci* **24**, 25–31 (2001).
40. Frade, J. M. & Ovejerro-Benito, M. C. Neuronal cell cycle: the neuron itself and its circumstances. *Cell Cycle* **14**, 712–720, https://doi.org/10.1080/15384101.2015.1004937 (2015).
41. Anzilotti, S. *et al.* Preconditioning, induced by sub-toxic dose of the neurotoxin L-BMAA, delays ALS progression in mice and prevents Na(+)/Ca(2+) exchanger 3 downregulation. *Cell Death Dis* **9**, 206, https://doi.org/10.1038/s41419-017-0227-9 (2018).
42. Mork, C. N., Faller, D. V. & Spanjaard, R. A. Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. *FEBS Lett* **581**, 5440–5444, https://doi.org/10.1016/j.febslet.2007.10.046 (2007).

**Acknowledgements**
This work was supported by a grant from Fukuoka Women's University. We thank Ms Miki Bando (Kumamoto University School of Medicine, Core Laboratory for Medical Research and Education) for technical assistance for flow cytometry.

**Author Contributions**
S.H. conceived and designed the experiments. S.O., S.E., K.H. and S.H. performed the experiments and analyzed the data. S.O. and S.H. wrote the manuscript and prepared the figures.

**Additional Information**
Competing Interests: The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2018